Locally advanced pancreatic cancer

Researchers are testing whether adding two oral drugs, avutometinib and defactinib, to standard chemotherapy (mFOLFIRINOX) is safe and can slow or shrink pancreatic ductal adenocarcinoma. The trial has two parts: one for people whose cancer has spread, and one for people whose ca…

This trial tests whether adding an experimental immunotherapy (SHR-1701) and a targeted drug (apatinib) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with advanced pancreatic cancer. The study enrolls adults aged 18 to 75 who have not yet received trea…

This clinical trial tests whether adding focused ultrasound (IMD10) to standard chemotherapy can help people with borderline resectable or locally advanced pancreatic cancer. The study will enroll 136 adults aged 18-85 with confirmed pancreatic ductal adenocarcinoma. Half will ge…

This early-stage trial tests a personalized cancer vaccine called ODI-2001 in 77 people with advanced colon or pancreatic cancer that has spread or cannot be removed. The vaccine is custom-made for each patient's tumor and is given along with a drug that boosts the immune system.…

This study tests whether injecting chemotherapy directly into a pancreatic tumor using an endoscope (EUS-guided) plus standard chemo works better than standard chemo alone. About 20 adults with locally advanced pancreatic cancer will take part. The goal is to see if the combinati…

This study tests whether a specific sequence of two different chemotherapy combinations, each paired with an immunotherapy drug (PD-L1 antibody), can shrink borderline resectable or locally advanced pancreatic cancer enough to allow surgical removal. About 77 adults with this typ…

This study looks at a new way to detect cancer cells in the portal vein blood of people with pancreatic cancer. The goal is to see if these cells can warn early if the cancer comes back or spreads. The study will involve 20 participants and uses a special ultrasound-guided proced…